This past year saw a lower-than-usual number of new drugs approved by the Food and Drug Administration, due in part to delays at the agency, according to published reports.
Combining a diabetes drug marketed by Eli Lilly and Amylin Pharmaceuticals controls blood sugar and promotes weight loss more than insulin alone, according to a new study.